# EDGAR Filing Document

**Accession Number:** 0001771910
**File Stem:** 0000950103-23-000092
**Filing Date:** 2023-1
**Character Count:** 8135
**Document Hash:** 938295d42169f3b59c90d9381a60eb35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-000092.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0000950103-23-000092

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230104

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADC Therapeutics SA
- **CENTRAL INDEX KEY:** 0001771910
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39071
- **FILM NUMBER:** 23506184

**BUSINESS ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
- **BUSINESS PHONE:** 41 21 653 02 00

**MAIL ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K** ****

<br> **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January 2023.

------

**Commission File Number: 001-39071**

**ADC Therapeutics SA**

**(Exact name of registrant as specified in its charter)**

**Biopôle**

**Route de la Corniche 3B**

**1066 Epalinges**

**Switzerland**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ADC Therapeutics SA** | **ADC Therapeutics SA** |
| Date: January 4, 2023 |  |  |
|  | By: | /s/ Peter J. Graham |
|  | Name: | Peter J. Graham |
|  | Title: | Authorized Signatory |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Press release dated January 4, 2023 |

---

## Exhibit 99.1

![](image_001.jpg)

**ADC Therapeutics to Participate in the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference**

**LAUSANNE, Switzerland, January 4, 2023** – ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11<sup>th</sup> at 3:00 p.m. PT.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, <u>ir.adctherapeutics.com</u>. A replay of the webcast will be available for approximately 30 days.

**About ADC Therapeutics**

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit <u>https://adctherapeutics.com/</u> and follow the Company on <u>Twitter</u> and <u>LinkedIn</u>.

ZYNLONTA<sup>®</sup> is a registered trademark of ADC Therapeutics SA.

**Forward-Looking Statements**

**This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability to continue to commercialize ZYNLONTA**<sup>®</sup> **in the United States and future revenue from the same; Swedish Orphan Biovitrum AB (Sobi**<sup>®</sup>**) ability to successfully commercialize ZYNLONTA**<sup>®</sup> **in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; our strategic partners', including Mitsubishi Tanabe Pharma Corporation and Overland Pharmaceuticals, ability to obtain regulatory approval for ZYNLONTA**<sup>®</sup> **in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the Company's ability to market its products in compliance with applicable laws and regulations; the timing and results of the Company's or its partners' research projects or clinical trials including LOTIS 2, 5 and 9, ADCT 901, 601 and 212, the timing and outcome of regulatory submissions and actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates; projected revenue and expenses,** the Company's indebtedness including Healthcare Royalty Management and Oak Tree facilities and the restrictions imposed on the Company's activities by such indebtedness, the

ability to repay such indebtedness and the significant cash required to service such indebtedness**; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.**

**Investors**

Eugenia Litz

ADC Therapeutics

<u>Eugenia.Litz@adctherapeutics.com</u>

+44 7879 627205

Amanda Loshbaugh

ADC Therapeutics

<u>Amanda.Loshbaugh@adctherapeutics.com</u>

+1 917-288-7023

**Media**<br> Mary Ann Ondish<br> ADC Therapeutics<br> <u>Maryann.Ondish@adctherapeutics.com</u>

+1 914-552-4625